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Background: Radiation can be used effectively for diagnosis and medical treatment, but it can also cause cancers
later on. Children with congenital heart disease frequently undergo cardiac catheterization procedures for
diagnostic or treatment purposes. Despite the clear clinical benefit to the patient, the complexity of these
procedures may result in high cumulative radiation exposure. Given children’s greater sensitivity to radiation and
the longer life span during which radiation health effects can develop, an epidemiological cohort study is being
launched in France to evaluate the risks of leukaemia and solid cancers in this specific population.
Methods/design: The study population will include all children who have undergone at least one cardiac
catheterization procedure since 2000 and were under 10 years old and permanent residents of France at the time
of the procedure. Electronically stored patient records from the departments of paediatric cardiology of the French
national network for complex congenital heart diseases (M3C) are being searched to identify the children to be
included. The minimum dataset will comprise: identification of the subject (file number in the centre or
department, full name, sex, date and place of birth), and characteristics of the intervention (date, underlying disease,
type of procedure, technical details, such as fluoroscopy time and dose area product, (DAP), which are needed to
reconstruct the doses received by each child). The cohort will be followed up through linkage with the two French
paediatric cancer registries, which have recorded all cases of childhood leukaemia and solid cancers in France since
1990 and 2000, respectively. Radiation exposure will be estimated retrospectively for each child. 4500 children with
catherizations between 2000 and 2011 have been already included in the cohort, and recruitment is ongoing at the
national level. The study is expected to finally include a total of 8000 children.
Discussion: This French cohort study is specifically designed to provide further knowledge about the potential
cancer risks associated with paediatric cardiac catheterization procedures. It will also provide new information on
typical dose levels associated with these procedures in France. Finally, it should help improve awareness of the
importance of radiation protection in these procedures.
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The main source of artificial radiation exposure in the
general population is exposure for medical purposes [1].
In France, this accounts for 40% of the annual exposure
of the entire population. Most of this exposure is related
to diagnostic procedures, which are associated with low
levels of ionising radiation. Despite recent technological
innovations that reduce the doses delivered, the in-
creased frequency of medical procedures has resulted in
an increase in overall population exposure to ionising ra-
diation, especially in the youngest and oldest age groups.
A study conducted by the IRSN (Institute for Radio-
logical Protection and Nuclear Safety) and the InVS
(French Institute for Public Health Surveillance), based
on health insurance records and a survey of a sample of
hospitals, estimated that about 74.6 million diagnostic
procedures using ionising radiation were performed in
2007 in France [2]. Moreover, recent years have seen an
increase in the frequency of relatively high dose proce-
dures, such as computed tomography (CT) scanning [3]
and interventional procedures in cardiology [4-6].
Cardiac catheterization procedures (CCP) are medical
interventions in which fluoroscopy is used to guide
probes and guidewires into the circulatory system, to ob-
tain hemodynamic and/or anatomical information for
diagnostic purposes or to place a variety of devices, such
as balloons, plugs and stents (Table 1) to correct or pal-
liate various cardiac problems, for treatment purposes.
The live birth incidence of congenital heart defects
(CHD) is around 0.8% [7,8], and one sixth of the infants
with CHD in developed countries will undergo CCP.
With the technological progress, the role of the CCP has
changed, moving from diagnostic to therapeutic. Thera-
peutic CCP have now become first line therapy forTable 1 Indications for diagnostic and therapeutic cardiac
catheterization procedures in paediatrics (from [5])
Main indications for diagnostic cardiac catheterization procedures in
pediatrics
1 - Pulmonary arterial hypertension
2 - Pulmonary artery angiographies
3 - Evaluation of intracardiac shunts
Main indications for therapeutic cardiac catheterization procedures in
pediatrics
1 - Balloon dilatation (valves) - Valvuloplasty
2 - Balloon dilatation (vessels) – Angioplasty
3 - Patent Arterial Duct (PAD) closure
4 - Atrial Septal Defect (ASD) closure
5 - Ventricular Septal Defect (VSD) closure
6 - Embolisation of abnormal vessels
7 - Hybrid proceduresseveral specific CHD; they account for almost two thirds
of CCP in expert centers. Although radiation doses dur-
ing CCP are lower than in the past, procedures last lon-
ger as they have become more complex being mostly
interventional [9].
Several recent studies have investigated radiation
doses in paediatric CCP [6,9-14]. These numbers re-
main limited in comparison with adult studies, prob-
ably due to the smaller number of centres performing
these paediatric procedures [13]. Thus far, published
doses for paediatric CCP, often available as effective
doses (Table 2), range from 2.2 mSv to 12 mSv [14] for
different types of standard paediatric CCP. But there is
a wide variation in dose from one CCP to another and
from one child to another (in particular, the child’s
weight at the time of the procedure is a key factor to
consider). The multiplicity of interventions in the same
child can eventually lead to a non-negligible cumula-
tive dose. Significant variation between paediatric car-
diology units is also expected, as they use different
machines and have operators of widely different levels
of experience.
Epidemiological studies of cancer risks following
diagnostic radiation exposure in children
Short-term effects of ionising radiation result primarily
from irradiation at high doses. The severity of these ef-
fects is then directly proportional to the dose received;
the effects are deterministic. For low doses, however, the
effects are stochastic: they appear later, randomly, and
their probability of occurrence increases with dose. Can-
cer is the most frequent of these stochastic effects [1]. It
appears to be of greatest concern for children as several
studies suggest that they are more susceptible than
adults to the effects of ionising radiation: for a given
dose, exposure during childhood is associated with a risk
of cancer greater than if it had been received during
adulthood [15]. Children also have more remaining years
of life during which a radiation-induced cancer could
develop. Cancers occur after a latency period, which evi-
dence suggests is at least 5 to 10 years for most solid
cancers and approximately 2 years for leukaemia.
Over the past 30 years, researchers have collected
large quantities of epidemiological data about popula-
tions (all ages) exposed to ionising radiation for medical
(therapeutic or diagnostic) purposes [16,17]. These stud-
ies are difficult to compare because they include popula-
tions of very different sizes (from a few hundred to
several thousand patients), they are heterogeneous in
age since some include children but also young adults,
and their methodological quality varies widely [18]. The
types of radiation considered also vary, as do the target
organs and the exposure period — all factors that
strongly affect dose.
Table 2 Effective dose (mSv) for diagnostic and therapeutic paediatric CCP from the literature
Study Year Diagnostic Therapeutic
Min Median Mean Max Min Median Mean Max
Bacher 2005 0.6 4.6 23.2 1.0 6.0 37.0
Onnash 2007 3.6 5 *
Yakoumakis 2009 0.16 2.90 3.71 16.44 0.38 5.00 25.01
El Sayed 2011 3.4 5.9
(*) Range from 2.16 to 12.1, depending on the type of procedure.
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multiple diagnostic X-rays during childhood or adoles-
cence to monitor tuberculosis or scoliosis have reported a
risk of breast cancer that increased with dose and the
number of radiographs [19-22]. It should be noted that
the cumulative dose to the breast was relatively high,
around 0.8 to 0.9 gray for tuberculosis follow-up [19,21]
and 0.11 gray for monitoring scoliosis [20]. Case–control
studies have found conflicting results, some showing an
increased risk of cancer after exposure to radiological ex-
aminations in childhood [23-25], others finding no in-
creased risk [26-28]. A first study analysing the risk of
developing cancer after repeated CT examinations in the
UK has just appeared [29]. The authors, assuming the typ-
ical doses used since 2001, suggest that 2-3 CT scans of
the head could triple children’s risk of brain cancer and
that 5-10 might triple their risk of leukaemia.
Only two cohort studies have assessed the association
between the risk of cancer in children and radiation ex-
posure during paediatric CCP. MacLaughlin studied
4891 Canadian children who had undergone at least one
cardiac CCP before the age of 18 years between 1946
and 1968 and did not demonstrate a significant increase
in leukaemia or in any other tumours in this population
[30]. A second study, conducted by Modan, examined
the records of 674 children who had undergone CCP for
CHD between 1950 and 1970 and showed an excess
number of solid cancers and of lymphomas [31]. Meth-
odological limitations (no estimation of the doses re-
ceived, types of CCP used unknown) might explain the
inconsistency of these results. More recently, Ait-Ali ap-
plied risk models in the literature [32] and estimated a
lifetime attributable risk of death from cancer equal to 1
in 1717 (0.06%) for boys (from 0 to 15 years) receiving
an average of 7.1 mSv and equal to 1 in 859 (0.12%) in
girls receiving an average of 9.4 mSv during CCP [33].
However, the available models, which are based mainly
on Hiroshima and Nagasaki A-bomb survivors, have
only limited information on the risk of cancer after ex-
posure in early childhood [34].
In this context, our research project is the direct epi-
demiological follow-up of children who underwent CCP
to evaluate their health status in terms of cancer and
leukaemia.Methods/design
Study aims
The objective of the study is to set up a cohort of chil-
dren who underwent at least one CCP before the age of
10 years from 2000 through 2013 and assess their risk of
solid cancer and leukaemia associated with radiation
exposure from CCP during childhood. More specifically,
the constitution of the cohort will allow us:
- To characterise the paediatric population that
underwent CCP in France from 2000 through 2013;
- To obtain new information on typical dose levels for
paediatric CCP in France during this period;
- To study the hypothesis of an excess risk of solid
cancers and leukaemia attributable to ionising radiation
exposure during CCP in children, by quantifying the
dose response relation between radiation exposure and
cancer risk and analysing potential modifying factors
(age at first exposure, sex, etc.).
- To improve awareness of the importance of radiation
protection during CCP in children.
Type of protocol
A cohort study is being conducted. The principle of this
type of protocol is the identification of a group of indi-
viduals about whom certain exposure information is col-
lected (here children under 10 years old at the time of
first CCP). The group is then followed forward in time
to ascertain the occurrence of the diseases of interest
(here solid cancer and leukaemia), so that for each indi-
vidual, prior exposure information can be related to sub-
sequent disease experience [35].
Population and setting
The study population consists of patients who under-
went at least one CCP (either for diagnostic or thera-
peutic purposes) before the age of 10 years and from 1
January, 2000, through 31 December, 2013 (Figure 1).
Because of the lack of a national adult cancer registry,
our study focuses on children exposed very young so
that we can follow them in incidence data for at least
10 years, through the French paediatric cancer registries.
CCP in children are predominantly performed in ter-
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Figure 1 General overview of the study design.
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for Complex Congenital Cardiac Defects-M3C, which
treats about 80% of the children with CHD in France. In
all, 4500 children recruited from the two centres coord-
inating the M3C-network (Necker Enfants malades,
Paris, and Centre Chirurgical Marie Lannelongue, Le
Plessis-Robinson) have already been included in the co-
hort. Recruitment is ongoing in these two centres and
will be extended to other centres of the M3C network.
The study is expected to finally include about 8000 chil-
dren. This estimation is based on the average number of
paediatric CCP performed in the two coordinating cen-
ters. These 8000 children, followed up for 15 years,
should contribute about 120, 000 person-years. During
the follow-up period, the expected number of solid can-
cers (from all causes) is 16 and the expected number of
leukaemia cases 6 (Table 3). Thus, the cohort will have a
statistical power of 80% to detect a SIR equal to 1.7 for
solid cancers and 2.07 for leukaemia (with α = 0.05).
Data available for the cohort
Electronically stored patient records from the depart-
ments of paediatric cardiology of tertiary hospitals inTable 3 Smallest measurable SIRs for cancer and
leukaemia for different scenarios (adapted from: [36])
Cohort size 8,000 25,000 32,000
Follow-up duration (years) 15 15 15
Person-years 120,000 375,000 480,000
Expected number of childhood
cancer cases in the cohorta
16 51 65
Smallest measurable SIR (all cancers)b 1.7 1.4 1.3
Expected number of childhood leukaemia
cases in the cohorta
5.6 17.6 22.6
Smallest measurable SIR (all leukaemia)b 2.1 1.6 1.5
a The annual standardised incidence rate of childhood cancer per 100,000 for
the period 2000-2004 in France was 15.6 for all cancers and 4.6 for leukaemia
(source: [37]).
b Smallest measurable SIR with α = 0.05 and β = 0.02.France are being searched to identify the children to be
included. The minimum dataset will comprise: iden-
tification of the patient (file number in the centre or
service, full name, sex, date and place of birth and char-
acteristics of the CCP (date of the procedure, age,
weight, underlying disease, type of procedure, technical
details including but not limited to fluoroscopy time and
dose area product (DAP)).
Follow-up of the children
Health status will be followed up by assessments in the
future and every five years from 2014 (Figure 1). The
vital status of each child will be identified by cross-
linkage with the national vital status registry (Répertoire
National d’Identification des Personnes Physiques
(RNIPP)).
Up to age 15, follow-up of cancer incidence will be
performed though cross linkage with the paediatric can-
cer registries (Registre des Tumeurs Solides de l’Enfant
(RTSE) and Registre National des Hemopathies de
l’Enfant (RNHE)), which since 1990 and 2000, respect-
ively, have recorded all cases of childhood (i.e., under
15 years old at diagnosis) leukaemia and cancers in
France. Above the age of 15 years, follow-up will be
based on mortality status as France has no national can-
cer registry for adult cancers. Follow-up of morbidity
through data from the medical insurance system (specif-
ically, the SNII-RAM, an inter-health insurance scheme
information system) may be available in the future.
Dose assessment
Individual CCP-related doses will be assessed for each
child included in the cohort (Figure 1). Exposure param-
eters (DAP, fluoroscopy time) will be retrieved from the
dose-recording system. The DAP, which represents the
dose in air measured at a given distance from the X-ray
tube multiplied by the area of the x-ray at that distance
[33], will be used as a surrogate for radiation exposure
[9]. Organ doses, especially to the lung, the oesophagus,
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software [38]. After the development of several assump-
tions, this programme, based on the Monte Carlo
method and developed to calculate patients’ organ doses
in medical examinations, could be used for the simula-
tion of CCP [39].
The proposed study does not consider radiation ex-
posure outside the participating centres. However, it is
planned to address the children’s exposure to CT scans,
which account for a major contribution to their medical
exposure dose. We will be able to cross-match our data
with data from the childhood French CT-scan cohort
(“Cohort Enfant Scanner”) set up by the IRSN [3] for the
children included in both cohorts. For children who
underwent CCP in centres not participating in the
“Enfant Scanner” scanner, it will be necessary to go back
to medical files to obtain information about the CT
scans performed.
Planned analysis
A detailed analysis plan was prepared as part of the
protocol. The statistical analyses will comprise:
– A description of the paediatric population that
underwent CCP in France from 2000 through 2013
(age, disease, etc.);
– Description of the doses from paediatric CCP;
– A comparison of the incidence of childhood cancers
and leukaemia in the cohort with that of the French
paediatric population.
Depending on the statistical power available, it should
be possible to quantify the dose–response relation be-
tween the irradiation received during CCP and the oc-
currence of cancer or leukaemia in childhood or
adulthood. Modifying factors, such as age at exposure
and sex, will be also considered in the risk modelling.
Ethical aspects
The French national data protection authority (Commis-
sion Nationale Informatique et Liberté (CNIL)) (n° 911112
of December 12, 2011) has approved the study and the
conditions of storage of personal data and use of
anonymised dosimetric and clinical data.
Associated teams and partnership added value
The study will be conducted by the Laboratory of Epi-
demiology of the Institute of Radioprotection and Nuclear
Safety (IRSN) in close collaboration with IRSN’s Medical
Expertise Unit (UEM) for dosimetric expertise and with
the paediatric cardiology units participating in this study.
The follow-up of the cohort for incidence of solid cancers
and leukaemia will be based on collaboration with the na-
tional registries of paediatric cancers (RTSE and RNHE).Collaboration is also planned with researchers from
the University of Newcastle (UK), where Dr M Pearce’s
group is conducting a similar study.
The complementary expertise of the three units work-
ing together — in paediatric cardiology (Reference
Centre for Complex Congenital Cardiac Defects –M3C,
Hôpital Necker), medical dosimetric expertise (Unit of
Medical Expertise of IRSN), and epidemiology in the
field of ionising radiation (Laboratory of Epidemiology
of IRSN) — is a major strength of this study.
This research will also benefit from the experience
developed in the Cohort Enfant Scanner study, also
conducted by the IRSN Laboratory of Epidemiology.
This national cohort now includes nearly 90 000 chil-
dren [3]. The French data are integrated in the European
EPI-CT project, which is coordinated by the Inter-
national Agency for Research on Cancer (IARC), (ref.
http://epi-ct.iarc.fr/).
Time plan
Initial inclusion data collection began in October 2011
and will continue through 2013. Thus, as early as 2014,
the statistical analysis will provide the first answers about
characteristics of the paediatric population undergoing
CCP in France, of doses from paediatric CCP, and on the
incidence of cancers in this population. Subsequent ana-
lyses of cancer risk will be conducted periodically.
Discussion
CCP play a crucial role in the diagnosis and treatment of
congenital heart diseases. The justification of these pro-
cedures is clear: they make it possible to avoid compli-
cated invasive surgery. These procedures are, however,
among the radiological procedures with the highest pa-
tient radiation dose. In the study by Ait-Ali, conven-
tional x-ray examinations accounted for 5% of the
collective effective dose and three types of procedures
were responsible for the remaining 95%: diagnostic CCP,
therapeutic CCP and CT scans [33]. Several authors have
discussed the long-term effects, such as cancer, following
diagnostic radiation exposure in children [16-18]. How-
ever, information on cancer risks associated with CCP
during early childhood nonetheless remains limited, and
authors have stressed the utility of setting up epidemio-
logical studies on the cancer risks associated with radi-
ation exposure during CCP [40]. Such a study is more
feasible today than in the past, for the long-term out-
come of the underlying cardiac diseases has improved
greatly in the past decade, and now excellent long-term
survival is the rule, rather than the exception [33]. Adult
survivors of surgically repaired CHD are a large and
growing population, estimated to be one million in
the US in the year 2000, compared with an estimated
300 000 in 1980 [33].
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children who have undergone at least one CCP before the
age of 10 years to assess the risk of solid cancers and leu-
kaemia associated with radiation exposure. The inclusion
of the children is currently ongoing via the French na-
tional network for Complex Congenital Cardiac defects-
M3C. As most CCP are performed during the first year of
life, our cohort will include very young children. Focusing
our study on young children will also allow us to follow
them in incidence data for at least 10 years, through
the French paediatric cancer registries. Nevertheless, due
to the medical context, this population of children is
characterised by very good medical follow-up with regular
medical visits. Specifically, details regarding the child’s
health at the time of the CCP will be reliably available
from the French hospital discharge summary database
(programme de médicalisation des systèmes d’information,
PMSI), based upon diagnosis-related groups (DRG) [41].
This will make it possible to take into account such
confounding factors as Down Syndrome, which is known
to be associated with both cancer and heart defects.
The previous absence of any such cohort in France
highlights the novelty of the project at the national level.
A similar study is currently being conducted in the UK
by Dr M. Pearce, University of Newcastle, and the feasi-
bility of a pooled analysis to increase the statistical
power of these individual studies is under discussion.
Even with complete and accurate follow-up, it must be
acknowledged that our study by itself will have limited
statistical power. The size of the French cohort was esti-
mated based on the average number of CCP performed
in the two main centres (Necker Enfants malades and
Centre Chirurgical Marie Lannelongue). As indicated in
Table 3, this sample size will be sufficient to detect an
overall excess risk of 1.7 for all cancer incidence, but
smaller levels are expected. Pooling data from France with
data from UK will allow detecting small excess risk of 1.3.
A key aspect of the proposed study will be the assess-
ment of individual doses received by children during CCP.
In general, radiation doses increase with age and proced-
ural complexity [42]. But acquisition data, tube angulation,
total fluoroscopy time and total cinematography time de-
pend strongly on the complexity of the CHD, the patient’s
size and morphology, and on the physician’s technical
skills and experience [39]. Both of the major participating
paediatric cardiology departments (Hospital Necker and
Chirurgical Centre Marie Lannelongue) have highly stable
staff, which reduces the variability around the dose due to
an operator effect.
However, there is a wide variation in the doses between
different CCP as there is no standard protocol for this
procedure, which is actually many different types of proce-
dures. Moreover, paediatric cardiac patients are a relatively
inhomogeneous group in the sense that there are manydifferent types of CHD in children that require different
types of procedures. Consequently, the radiologic inter-
ventions do not generally follow a standardised scheme.
Furthermore, it is a relatively young and rapidly evolving
field. Although some groups share similar nomenclature
systems or coding lists, the field has not yet adopted a
comprehensive and universally accepted nomenclature
system for CCP [43]. Nevertheless, a common language,
or system of nomenclature, is imperative as the study will
be carried out in several centres in France. Principally, two
broad categories will be defined: diagnostic CCP and
therapeutic CCP. Subcategories for therapeutic CCP have
been identified according to their main indications in chil-
dren: valvuloplasty, angioplasty, patent arterial duct (PAD)
closure, atrial septal defect (ASD) closure, and ventricular
septal defect (VSD) closure.
The estimation of individual doses is also complicated
by the fact that the image acquisition parameters for cal-
culating the dose level of a given body are rarely available.
In our study, the magnitudes recorded automatically in
recent years are the fluoroscopy time and the DAP (Dose
Area Product). The effective dose can be calculated from
these quantities and can be used to compare between dif-
ferent procedures. Nevertheless, the effective dose is a
quantity calculated from tissue weighting factors unrelated
to sex and age, defined by the International Commission
on Radiological Protection [44], and it does not take
into account the increased radiosensitivity of children
compared to adults. To obtain more comprehensive
information on children’s exposure during CCP, our
research project will calculate organ doses, including to
the lungs, oesophagus, and thyroid, with appropriate
software (PCXMC) [38].
By addressing the exposures received during childhood,
our research will provide some answers about individual
variability in cancer risk, particularly, about the effect of
age at exposure. Other large-scale studies on the effects of
medical exposure in childhood have been developed in
France over the past five years. The European project
EPI-CT (Epidemiological study to quantify risks for paedi-
atric computerised tomography and to optimise doses)
study, currently underway at the international level, is
designed to gather data from nine national cohorts of chil-
dren undergoing one or more CT scans to determine
whether there is an excess of cancer cases attributable to
CT exposure during childhood [3,29,36]. Another study
examining the health effects of medical exposure during
childhood is ELFE (Etude Longitudinale Française depuis
l’Enfance), launched in April 2011 in France [45], intended
to follow 20,000 children from birth to adulthood and ana-
lyse the impact of various factors (social, environmental,
nutritional, etc.) on their physical, psychological and social
development. Medical exposure to ionising radiation is
one of these factors and will be collected prospectively
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ation (radiography, CT scans, etc.), the number, and the
anatomical zone explored.
Conclusion
Technological advances have made it possible for CCP
to play a therapeutic as well as a diagnostic role. In vari-
ous CHD, it can allow surgical procedures to be post-
poned or even replaced. But CCP can also involve
potentially non-negligible doses of radiation to the pa-
tients. This issue is particularly relevant for children as
they are relatively more sensitive to ionising radiation
than adults are and have a longer mean lifetime expect-
ancy. Our cohort study is specifically designed to pro-
vide further knowledge on the potential cancer risk
associated with paediatric CCP. This nationwide study
will provide comprehensive information on typical levels
of doses for paediatric interventional cardiology proce-
dures in France. In the meantime, it is very important to
optimise procedures and keep doses to paediatric pa-
tients as low as possible.
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